Advertisement AstraZeneca enters $510m Heptares deal to develop new immuno-oncology treatments - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

AstraZeneca enters $510m Heptares deal to develop new immuno-oncology treatments

AstraZeneca and Sosei Group's subsidiary Heptares Therapeutics have entered into an agreement to develop new immuno-oncology treatments.

AstraZeneca Headquarters London

The deal will see AstraZeneca acquire exclusive global rights from Heptares to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

Both the firms will also collaborate to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.

As part of the deal, AstraZeneca will pay an initial $10m for exclusive global rights to HTL-1071 and could pay more than $500m following successful completion of development and commercialisation milestones of the product.

AstraZeneca Innovative Medicines and Early Development Unit Oncology head and vice-president Susan Galbraith said: "We are pleased to expand our successful collaboration with Heptares into the exciting area of immuno-oncology.

"By combining the pioneering A2A receptor programme with the strength of AstraZeneca’s oncology portfolio, we hope to develop novel treatments with the potential to transform the lives of patients."

The deal will see AstraZeneca explore the assets across a range of cancers as well as in combination with its existing portfolio of immunotherapies.


Image: AstraZeneca headquarters in London, UK. Photo: courtesy of AstraZeneca plc.